NCT02925416View on ClinicalTrials.gov

Safety of Either a Single or Two Intravenous Doses of Orbactiv in Participants With Acute Bacterial Skin and Skin Structure Infection

PHASE4CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

January 24, 2017

Primary Completion Date

June 20, 2017

Study Completion Date

June 20, 2017

Conditions
Skin Diseases, Bacterial
Interventions
DRUG

Oritavancin

Administered intravenously

DRUG

Placebo (D5W)

Administered intravenously

Trial Locations (1)

08244

South Jersey Infectious Disease, Somers Point

Sponsors
All Listed Sponsors
lead

The Medicines Company

INDUSTRY